Clinical Trial: EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07339527) titled 'EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas' on Dec. 20, 2025.

Brief Summary: This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of EZH2 inhibitor Zeprumetostat in combination therapy for patients with relapsed or refractory mature T-cell and NK-cell lymphomas.

Study Start Date: Jan. 01

Study Type: INTERVENTIONAL

Condition: Mature T-cell and NK-cell Lymphoma

Intervention: DRUG: Zeprumetostat

350mg, po, bid

DRUG: Golidocitinib

Cohort 1: Golidocitinib: 150mg, po, qd

DRUG: Chidamide...